NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $11.04 -0.35 (-3.07%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$11.07 +0.03 (+0.27%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Keros Therapeutics Stock (NASDAQ:KROS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$10.95▼$11.5950-Day Range$9.17▼$12.0052-Week Range$8.98▼$22.55Volume208,691 shsAverage Volume188,630 shsMarket Capitalization$216.60 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions. These programs are investigational and are not approved treatments. Founded in 2015 and based in Lexington, Massachusetts, Keros conducts research and clinical development with the aim of serving patients in multiple markets. Cofounder Jasbir Seehra has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreKROS MarketRank™: 2.902170887835 of 5 starsKeros Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 277th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingKeros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKeros Therapeutics has a consensus price target of $20.00, representing about 81.2% upside from its current price of $11.04.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($3.36) to ($5.12) per share.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.27% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 7.06.Change versus previous monthShort interest in Keros Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.50 News SentimentKeros Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for KROS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,206.00 in company stock.Percentage Held by Insiders12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KROS Stock News HeadlinesKeros Therapeutics Authorizes Additional $5 Mln Share Repurchase ProgramNovember 17, 2026 | rttnews.comKeros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares.November 16, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 21 at 1:00 AM | Base Camp Trading (Ad)Keros Therapeutics launches $5M share buyback programNovember 16, 2026 | msn.comKeros Therapeutics Announces Additional $5 Million Share Repurchase AuthorizationNovember 16, 2026 | globenewswire.comFY2026 EPS Forecast for Keros Therapeutics Lifted by AnalystNovember 12, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), ANI Pharmaceuticals (ANIP) and Keros Therapeutics (KROS)November 7, 2026 | theglobeandmail.comKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsNovember 6, 2026 | markets.businessinsider.comSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $20.36 at the beginning of 2026. Since then, KROS shares have decreased by 45.8% and is now trading at $11.04. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) posted its earnings results on Thursday, November, 5th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $1.66. The business earned $40.01 million during the quarter, compared to analysts' expectations of $14.76 million. Keros Therapeutics had a negative trailing twelve-month return on equity of 21.85% and a negative net margin of 256.60%. Is Keros Therapeutics doing a stock buyback? Keros Therapeutics' Board of Directors approved a stock repurchase program on Wednesday, September 9th 2026, which authorizes the company to buy back $5 million in shares, according to EventVestor. This means that the company could buy up to 2.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its stock is undervalued. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $90 million in an initial public offering on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Top institutional shareholders of Keros Therapeutics include Nantahala Capital Management LLC (7.59%), State Street Corp (2.76%), Goldman Sachs Group Inc. (1.30%) and Empowered Funds LLC (0.67%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Annita Tanini, Lorena Raquel Lerner, Jean Jacques Bienaime, Anne Prener, Charles W Newton, Julius Knowles, Nima Farzan, Alpna Seth, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Broadcom (AVGO), Marvell Technology (MRVL) and Micron Technology (MU). Company Calendar Last Earnings11/05/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KROS's financial health is in the Red zone, according to TradeSmith. KROS has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees92Year Founded2015Price Target and Rating Average Price Target for Keros Therapeutics$20.00 High Price Target$23.00 Low Price Target$18.00 Potential Upside/Downside+81.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$87.01 million Net Margins-256.60% Pretax Margin-153.25% Return on Equity-21.85% Return on Assets-19.83% Debt Debt-to-Equity RatioN/A Current Ratio18.14 Quick Ratio18.14 Sales & Book Value Annual Sales$244.06 million Price / Sales0.89 Cash Flow$5.00 per share Price / Cash Flow2.21 Book Value$14.22 per share Price / Book0.78Miscellaneous Outstanding Shares19,620,000Free Float17,151,000Market Cap$216.60 million OptionableOptionable Beta1.13 Social Links 7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and GoogleCould the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.Get This Free Report This page (NASDAQ:KROS) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.